- Previous Close
67.38 - Open
68.00 - Bid 65.55 x --
- Ask 66.00 x --
- Day's Range
65.55 - 68.00 - 52 Week Range
57.99 - 84.97 - Volume
3,040 - Avg. Volume
8,650 - Market Cap (intraday)
2.327B - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-3.85 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides specialty chemicals, skin care and hospital care products, and generics in India. The company offers specialty chemicals, including retinol, DL alpha tocopherol, D pantothenate, cyanocobalamin, pyridoxine Hcl, thiamine, nicotinic acid, water sol. vitamin E, coenzyme Q10, and D-biotin; and skin care products, such as best care hands, hands sanitizers, moisturizing creams, skinsure plus, skinsure ultra, alcohol gels, and barrier creams. It also provides hospital care products comprising hand rubs and gel, skin antiseptics, and general antiseptics and disinfectants; and generic products in the areas of orthopedic, neuro, and gastro, etc. In addition, the company offers contract research and manufacturing services. Pharmaids Pharmaceuticals Limited was incorporated in 1989 and is based in Bengaluru, India.
www.pharmaids.com25
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: PHARMAID.BO
View MorePerformance Overview: PHARMAID.BO
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHARMAID.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHARMAID.BO
View MoreValuation Measures
Market Cap
2.38B
Enterprise Value
2.49B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.12
Price/Book (mrq)
3.54
Enterprise Value/Revenue
8.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.18%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
297.71M
Net Income Avi to Common (ttm)
-113.67M
Diluted EPS (ttm)
-3.85
Balance Sheet and Cash Flow
Total Cash (mrq)
27.92M
Total Debt/Equity (mrq)
22.30%
Levered Free Cash Flow (ttm)
--